Clinical Trial Update: Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of bortezomib, paclitaxel, and carboplatin in unresectable, metastatic esophageal or gastroesophageal junction cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Velcade (bortezomib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED